Esophagus lymphoma

Summary

Esophagus lymphoma (MONDO:0001188) is a cancer. A subtype of gastrointestinal lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	esophagus lymphoma
Mondo ID	MONDO:0001188
DOID	DOID:1106
ICD-11	223819380
NCIT	C5687
UMLS	C1333459
MedGen	234231
GARD	0022896
Anatomy (UBERON)	UBERON:0001043
Is cancer (heuristic)	yes

Also known as: esophageal lymphoma · esophagus lymphoma · lymphoma of esophagus · lymphoma of oesophagus · lymphoma of the esophagus · lymphoma of the oesophagus · primary esophageal lymphoma

Disease family

This is a subtype of gastrointestinal lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › gastrointestinal lymphoma › esophagus lymphoma

Related subtypes (9): gastric lymphoma, small intestine lymphoma, pancreas lymphoma, splenic manifestation of prolymphocytic leukemia, splenic manifestation of hairy cell leukemia, gallbladder lymphoma, liver lymphoma, colorectal lymphoma, tonsillar lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.